Patents by Inventor Ronald Evans

Ronald Evans has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12637662
    Abstract: The invention features cells, islet-like cells, pancreatic islets and organoids (e.g., human islet-like organoids or HILOs), as well as cell cultures and methods that are useful for the rapid and reliable generation of cells and organoids, such as pancreatic islets and organoids, that are sustainable in vivo and that evade immune detection, rejection and autoimmunity. The invention also features methods of treating pancreatic diseases, such as type 2 diabetes, and pancreatic cancer, using the cells, islet-like cells, pancreatic islets and organoids (e.g., HILOs) that are designed to modulate the activity of immune cells that would otherwise react against them.
    Type: Grant
    Filed: October 11, 2019
    Date of Patent: May 26, 2026
    Assignee: SALK INSTITUTE FOR BIOLOGICAL STUDIES
    Inventors: Eiji Yoshihara, Ruth Yu, Michael Downes, Ronald Evans, Annette Atkins
  • Patent number: 12253527
    Abstract: The invention features compositions and methods treating or preventing for age-related insulin resistance, type 2 diabetes and related disorders. The method involves depleting fTreg cells with an anti-ST2 antibody to decrease age-related fTreg accumulation and restore insulin sensitivity, thereby treating age-related insulin resistance, type 2 diabetes and related disorders.
    Type: Grant
    Filed: July 19, 2022
    Date of Patent: March 18, 2025
    Assignee: Salk Institute for Biological Studies
    Inventors: Sagar P. Bapat, Ye Zheng, Ronald Evans, Michael Downes, Annette R. Atkins, Ruth T. Yu
  • Patent number: 11981931
    Abstract: The invention generally features compositions comprising induced pluripotent stem cell progenitors (also termed reprogramming progenitor cells) and methods of isolating such cells. The invention also provides compositions comprising induced pluripotent stem cells (iPSCs) derived from such progenitor cells. Induced pluripotent stem cell progenitors generate iPSCs at high efficiency.
    Type: Grant
    Filed: December 8, 2020
    Date of Patent: May 14, 2024
    Assignee: Salk Institute for Biological Studies
    Inventors: Ronald Evans, Michael Downes, Yasuyuki Kida, Teruhisa Kawamura, Zong Wei, Ruth T. Yu, Annette R. Atkins
  • Publication number: 20240101962
    Abstract: The invention features pancreatic islet and pancreatic organoids, and cell cultures and methods that are useful for the rapid and reliable generation of pancreatic islet and pancreatic islet organoids. The invention also features methods of treating pancreatic diseases and methods of identifying agents that are useful for treatment of pancreatic diseases, such as type 2 diabetes and pancreatic cancer, using the pancreatic islet and pancreatic organoids of the invention.
    Type: Application
    Filed: June 23, 2023
    Publication date: March 28, 2024
    Applicant: Salk Institute for Biological Studies
    Inventors: Ronald EVANS, Michael DOWNES, Annette ATKINS, Eiji YOSHIHARA, Ruth YU
  • Patent number: 11760977
    Abstract: The invention features pancreatic islet and pancreatic organoids, and cell cultures and methods that are useful for the rapid and reliable generation of pancreatic islet and pancreatic islet organoids. The invention also features methods of treating pancreatic diseases and methods of identifying agents that are useful for treatment of pancreatic diseases, such as type 2 diabetes and pancreatic cancer, using the pancreatic islet and pancreatic organoids of the invention.
    Type: Grant
    Filed: May 24, 2017
    Date of Patent: September 19, 2023
    Assignee: SALK INSTITUTE FOR BIOLOGICAL STUDIES
    Inventors: Ronald Evans, Michael Downes, Annette Atkins, Eiji Yoshihara, Ruth Yu
  • Patent number: 11685901
    Abstract: The invention features pancreatic islet and pancreatic organoids, and cell cultures and methods that are useful for the rapid and reliable generation of pancreatic islet and pancreatic islet organoids. The invention also features methods of treating pancreatic diseases and methods of identifying agents that are useful for treatment of pancreatic diseases, such as type 2 diabetes and pancreatic cancer, using the pancreatic islet and pancreatic organoids of the invention.
    Type: Grant
    Filed: March 28, 2022
    Date of Patent: June 27, 2023
    Assignee: Salk Institute for Biological Studies
    Inventors: Ronald Evans, Michael Downes, Annette Atkins, Eiji Yoshihara, Ruth Yu
  • Publication number: 20230078590
    Abstract: The invention features compositions and methods treating or preventing for age-related insulin resistance, type 2 diabetes and related disorders. The method involves depleting fTreg cells with an anti-ST2 antibody to decrease age-related fTreg accumulation and restore insulin sensitivity, thereby treating age-related insulin resistance, type 2 diabetes and related disorders.
    Type: Application
    Filed: July 19, 2022
    Publication date: March 16, 2023
    Applicant: Salk Institute for Biological Studies
    Inventors: Sagar P. BAPAT, Ye ZHENG, Ronald EVANS, Michael DOWNES, Annette R. ATKINS, Ruth T. YU
  • Publication number: 20220315901
    Abstract: The invention generally features compositions comprising induced pluripotent stem cell progenitors (also termed reprogramming progenitor cells) and methods of isolating such cells. The invention also provides compositions comprising induced pluripotent stem cells (iPSCs) derived from such progenitor cells. Induced pluripotent stem cell progenitors generate iPSCs at high efficiency.
    Type: Application
    Filed: December 8, 2020
    Publication date: October 6, 2022
    Applicant: SALK INSTITUTE FOR BIOLOGICAL STUDIES
    Inventors: RONALD EVANS, MICHAEL DOWNES, YASUYUKI KIDA, TERUHISA KAWAMURA, ZONG WEI, RUTH T. YU, ANNETTE R. ATKINS
  • Patent number: 11428697
    Abstract: The invention features compositions and methods treating or preventing for age-related insulin resistance, type 2 diabetes and related disorders. The method involves depleting fTreg cells with an anti-ST2 antibody to decrease age-related fTreg accumulation and restore insulin sensitivity, thereby treating age-related insulin resistance, type 2 diabetes and related disorders.
    Type: Grant
    Filed: December 4, 2019
    Date of Patent: August 30, 2022
    Assignee: SALK INSTITUTE FOR BIOLOGICAL STUDIES
    Inventors: Sagar P. Bapat, Ye Zheng, Ronald Evans, Michael Downes, Annette R. Atkins, Ruth T. Yu
  • Publication number: 20220220446
    Abstract: The invention features pancreatic islet and pancreatic organoids, and cell cultures and methods that are useful for the rapid and reliable generation of pancreatic islet and pancreatic islet organoids. The invention also features methods of treating pancreatic diseases and methods of identifying agents that are useful for treatment of pancreatic diseases, such as type 2 diabetes and pancreatic cancer, using the pancreatic islet and pancreatic organoids of the invention.
    Type: Application
    Filed: March 28, 2022
    Publication date: July 14, 2022
    Applicant: Salk Institute for Biological Studies
    Inventors: Ronald EVANS, Michael DOWNES, Annette ATKINS, Eiji YOSHIHARA, Ruth YU
  • Publication number: 20210363490
    Abstract: The invention features cells, islet-like cells, pancreatic islets and organoids (e.g., human islet-like organoids or HILOs), as well as cell cultures and methods that are useful for the rapid and reliable generation of cells and organoids, such as pancreatic islets and organoids, that are sustainable in vivo and that evade immune detection, rejection and autoimmunity. The invention also features methods of treating pancreatic diseases, such as type 2 diabetes, and pancreatic cancer, using the cells, islet-like cells, pancreatic islets and organoids (e.g., HILOs) that are designed to modulate the activity of immune cells that would otherwise react against them.
    Type: Application
    Filed: October 11, 2019
    Publication date: November 25, 2021
    Applicant: SALK INSTITUTE FOR BIOLOGICAL STUDIES
    Inventors: Eiji YOSHIHARA, Ruth YU, Michael DOWNES, Ronald EVANS, Annette ATKINS
  • Patent number: 10920199
    Abstract: The invention generally features compositions comprising induced pluripotent stem cell progenitors (also termed reprogramming progenitor cells) and methods of isolating such cells. The invention also provides compositions comprising induced pluripotent stem cells (iPSCs) derived from such progenitor cells. Induced pluripotent stem cell progenitors generate iPSCs at high efficiency. In particular embodiments the invention is predicated upon increased expression of an estrogen related receptor and changes in the oxidative and glycolytic pathways.
    Type: Grant
    Filed: February 26, 2016
    Date of Patent: February 16, 2021
    Assignee: SALK INSTITUTE FOR BIOLOGICAL STUDIES
    Inventors: Ronald Evans, Michael Downes, Yasuyuki Kida, Teruhisa Kawamura, Zong Wei, Ruth T. Yu, Annette R. Atkins
  • Publication number: 20200141947
    Abstract: The invention features compositions and methods treating or preventing for age-related insulin resistance, type 2 diabetes and related disorders. The method involves depleting fTreg cells with an anti-ST2 antibody to decrease age-related fTreg accumulation and restore insulin sensitivity, thereby treating age-related insulin resistance, type 2 diabetes and related disorders.
    Type: Application
    Filed: December 4, 2019
    Publication date: May 7, 2020
    Applicant: SALK INSTITUTE FOR BIOLOGICAL STUDIES
    Inventors: SAGAR P. BAPAT, YE ZHENG, RONALD EVANS, MICHAEL DOWNES, ANNETTE R. ATKINS, RUTH T. YU
  • Patent number: 10539572
    Abstract: The invention features compositions and methods treating or preventing for age-related insulin resistance, type 2 diabetes and related disorders. The method involves depleting fTreg cells with an anti-ST2 antibody to decrease age-related fTreg accumulation and restore insulin sensitivity, thereby treating age-related insulin resistance, type 2 diabetes and related disorders.
    Type: Grant
    Filed: January 12, 2016
    Date of Patent: January 21, 2020
    Assignee: SALK INSTITUTE FOR BIOLOGICAL STUDIES
    Inventors: Sagar P. Bapat, Ye Zheng, Ronald Evans, Michael Downes, Annette R. Atkins, Ruth T. Yu
  • Publication number: 20190211310
    Abstract: The invention features pancreatic islet and pancreatic organoids, and cell cultures and methods that are useful for the rapid and reliable generation of pancreatic islet and pancreatic islet organoids. The invention also features methods of treating pancreatic diseases and methods of identifying agents that are useful for treatment of pancreatic diseases, such as type 2 diabetes and pancreatic cancer, using the pancreatic islet and pancreatic organoids of the invention.
    Type: Application
    Filed: May 24, 2017
    Publication date: July 11, 2019
    Applicant: SALK INSTITUTE FOR BIOLOGICAL STUDIES
    Inventors: RONALD EVANS, MICHAEL DOWNES, ANNETTE ATKINS, EIJI YOSHIHARA, RUTH YU
  • Patent number: 10188627
    Abstract: Provided herein are compounds of formula (I) useful for the treatment of PPAR-delta related diseases (e.g. mitochondrial diseases, muscular diseases, vascular diseases, demyelinating diseases and metabolic diseases).
    Type: Grant
    Filed: October 7, 2015
    Date of Patent: January 29, 2019
    Assignees: Mitobridge, Inc., Salk Institute for Biological Studies
    Inventors: Michael Downes, Ronald Evans, Arthur Kluge, Bharat Lagu, Masanori Miura, Sunil Kumar Panigrahi, Michael Patane, Susanta Samajdar, Ramesh Senaiar, Taisuke Takahashi
  • Publication number: 20180267059
    Abstract: The invention features compositions and methods treating or preventing for age-related insulin resistance, type 2 diabetes and related disorders. The method involves depleting fTreg cells with an anti-ST2 antibody to decrease age-related fTreg accumulation and restore insulin sensitivity, thereby treating age-related insulin resistance, type 2 diabetes and related disorders.
    Type: Application
    Filed: January 12, 2016
    Publication date: September 20, 2018
    Applicant: SALK INSTITUTE FOR BIOLOGICAL STUDIES
    Inventors: SAGAR P. BAPAT, YE ZHENG, RONALD EVANS, MICHAEL DOWNES, ANNETTE R. ATKINS, RUTH T. YU
  • Publication number: 20180044642
    Abstract: The invention generally features compositions comprising induced pluripotent stem cell progenitors (also termed reprogramming progenitor cells) and methods of isolating such cells. The invention also provides compositions comprising induced pluripotent stem cells (iPSCs) derived from such progenitor cells. Induced pluripotent stem cell progenitors generate iPSCs at high efficiency. In particular embodiments the invention is predicated upon increased expression of an estrogen related receptor and changes in the oxidative and glycolytic pathways.
    Type: Application
    Filed: February 26, 2016
    Publication date: February 15, 2018
    Applicant: Salk Institute for Biological Studies
    Inventors: Ronald EVANS, Michael DOWNES, Yasuyuki KIDA, Teruhisa KAWAMURA, Zong WEI, Ruth T. YU, Annette R. ATKINS
  • Publication number: 20170305894
    Abstract: Provided herein are compounds of Formula (I) and compositions useful in increasing PPARS activity. The compounds and compositions provided herein are useful for the treatment of PPARS related diseases (e.g., muscular diseases, vascular disease, demyelinating disease, and metabolic diseases).
    Type: Application
    Filed: October 7, 2015
    Publication date: October 26, 2017
    Inventors: Thomas Baiga, Michael Downes, Ronald Evans, Arthur Kluge, Bharat Lagu, Masanori Miura, Sunil Kumar Panigrahi, Michael Patane, Susanta Samajdar, Ramesh Senaiar, Taisuke Takahashi
  • Publication number: 20170304255
    Abstract: Provided herein are compounds of formula (I) useful for the treatment of PPAR-delta related diseases (e.g. mitochondrial diseases, muscular diseases, vascular diseases, demyelinating diseases and metabolic diseases).
    Type: Application
    Filed: October 7, 2015
    Publication date: October 26, 2017
    Inventors: Thomas Baiga, Michael Downes, Ronald Evans, Arthur Kluge, Bharat Lagu, Masanori Miura, Sunil Kumar Panigrahi, Michael Patane, Susanta Samajdar, Ramesh Senaiar, Taisuke Takahashi